A General Framework for Treatment Effect Estimators Considering Patient Adherence

References

• Akacha, M., Bretz, F., Ohlssen, D., Rosenkranz, G., and Schmidli, H. (2017), “Estimands and Their Role in Clinical Trials,” Statistics in Biopharmaceutical Research, 9, 268–271. DOI: 10.1080/19466315.2017.1302358.
   Web of Science ®Google Scholar
• Akacha, M., Bretz, F., and Ruberg, S. (2017), “Estimands in Clinical Trials Broadening the Perspective,” Statistics in Medicine, 36, 5–19. DOI: 10.1002/sim.7033.
   PubMed Web of Science ®Google Scholar
• Austin, P. C. (2016), “Variance Estimation When Using Inverse Probability of Treatment Weighting (IPTW) With Survival Analysis,” Statistics in Medicine, 35, 5642–5655. DOI: 10.1002/sim.7084.
   PubMed Web of Science ®Google Scholar
• Ayele, B. T., Lipkovich, I., Molenberghs, G., and Mallinckrodt, C. H. (2014). “A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials,” Journal of Biopharmaceutical Statistics, 24, 211–228. DOI: 10.1080/10543406.2013.859148.
   PubMed Web of Science ®Google Scholar
• Bergenstal, R. M., Lunt, H., Franek, E., Travert, F., Mou, J., Qu, Y., Antalis, C. J., Hartman, M. L., Rosilio, M., Jacober, S. J., and Bastyr, E. J. (2016), “Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients With Type 1 Diabetes: IMAGINE 3,” Diabetes, Obesity and Metabolism, 18, 1081–1088. DOI: 10.1111/dom.12698.
   PubMedGoogle Scholar
• Bornkamp, B., and Bermann, G. (2019), “Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-to-Event Endpoint,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2019.1575280.
   Web of Science ®Google Scholar
• Carpenter, J. R., and Kenward, M. G. (2007), “Missing Data in Randomised Controlled Trials: A Practical Guide,” available at http://researchonline.lshtm.ac.uk/4018500/1/rm04_jh17_mk.pdf.
   Google Scholar
• Carpenter, J. R., Roger, J. H., and Kenward, M. G. (2013), “Analysis of Longitudinal Trials With Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation,” Journal of Biopharmaceutical Statistics, 23, 1352–1371. DOI: 10.1080/10543406.2013.834911.
   PubMed Web of Science ®Google Scholar
• Chiba, Y., and VanderWeele, T. J. (2011), “A Simple Method for Principal Strata Effects When the Outcome Has Been Truncated Due to Death,” American Journal of Epidemiology, 173, 745–751. DOI: 10.1093/aje/kwq418.
   PubMed Web of Science ®Google Scholar
• Cro, S., Morris, T. P., Kenward, M. G., and Carpenter, J. R. (2016), “Reference-Based Sensitivity Analysis via Multiple Imputation for Longitudinal Trials With Protocol Deviation,” The Stata Journal, 16, 443–463. DOI: 10.1177/1536867X1601600211.
   PubMed Web of Science ®Google Scholar
• Follmann, D., and Wu, M. (1995), “An Approximate Generalized Linear Model With Random Effects for Informative Missing Data,” Biometrics, 51, 151–168. DOI: 10.2307/2533322.
   PubMed Web of Science ®Google Scholar
• Frangakis, C. E., and Rubin, D. B. (2002), “Principal Stratification in Causal Inference,” Biometrics, 58, 21–29. DOI: 10.1111/j.0006-341X.2002.00021.x.
   PubMed Web of Science ®Google Scholar
• Garrett, A. (2015), “Choosing Appropriate Estimands in Clinical Trials (Leuchs et al). Letter to the Editor,” Therapeutic Innovation & Regulatory Science, 49, 601. DOI: 10.1177/2168479015586004.
   PubMed Web of Science ®Google Scholar
• Hernán, M. A., Brumback, B., and Robins, J. M. (2001), “Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments,” Journal of the American Statistical Association, 96, 440–448. DOI: 10.1198/016214501753168154.
   Web of Science ®Google Scholar
• Hirano, K., Imbens, G. W., and Ridder, G. (2003), “Efficient Estimation of Average Treatment Effects Using the Estimated Propensity Score,” Econometrica, 71, 1161–1189. DOI: 10.1111/1468-0262.00442.
   Web of Science ®Google Scholar
• Holland, P. W. (1986), “Statistics and Causal Inference,” Journal of the American Statistical Association, 81, 945–960. DOI: 10.1080/01621459.1986.10478354.
   Web of Science ®Google Scholar
• ICH E9 (1998), “International Conference on Harmonisation Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials,” available at http://www.ich.org.
   Google Scholar
• ICH E9 (R1) (2019). “International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.
   Google Scholar
• Imbens, G., and Angrist, J. (1994), “Identification and Estimation of Local Average Treatment Effects,” Econometrica, 62, 467–476. DOI: 10.2307/2951620.
   Web of Science ®Google Scholar
• Jin, H., and Rubin, D. B. (2008), “Principal Stratification for Causal Inference With Extended Partial Compliance,” Journal of the American Statistical Association, 103, 101–111. DOI: 10.1198/016214507000000347.
   Web of Science ®Google Scholar
• Laird, N. M., and Ware, J. H. (1982), “Random-Effects Models for Longitudinal Data,” Biometrics, 38, 963–974. DOI: 10.2307/2529876.
   PubMed Web of Science ®Google Scholar
• LaVange, L. M., and Permutt, T. (2016), “A Regulatory Perspective on Missing Data in the Aftermath of the NRC Report,” Statistics in Medicine, 35, 2853–2864. DOI: 10.1002/sim.6840.
   PubMed Web of Science ®Google Scholar
• Leuchs, A-K., Zinserling, J., Brandt, A., Wirtz, D., and Benda, N. (2015), “Choosing Appropriate Estimands in Clinical Trials,” Therapeutic Innovation & Regulatory Science, 49, 584–592. DOI: 10.1177/2168479014567317.
   PubMed Web of Science ®Google Scholar
• Li, F., Morgan, K. L., and Zaslavsky, A. M. (2018), “Balancing Covariates via Propensity Score Weighting,” Journal of the American Statistical Association, 113, 390–400. DOI: 10.1080/01621459.2016.1260466.
   Web of Science ®Google Scholar
• Lin, D. Y., and Wei, L. J. (1989), “The Robust Inference for the Cox Proportional Hazards Model,” Journal of the American Statistical Association, 84, 1074–1078. DOI: 10.1080/01621459.1989.10478874.
   Web of Science ®Google Scholar
• Little, R. J. (1993), “Pattern-Mixture Models for Multivariate Incomplete Data,” Journal of the American Statistical Association, 88, 125–134. DOI: 10.2307/2290705.
   Web of Science ®Google Scholar
• Little, R. J. A., and Rubin, D. B. (2002). Statistical Analysis with Missing data. New York: Wiley.
   Google Scholar
• Little, R., and Yau, L. (1996), “Intent-to-Treat Analysis for Longitudinal Studies With Drop-Outs,” Biometrics, 52, 1324–1333. DOI: 10.2307/2532847.
   PubMed Web of Science ®Google Scholar
• Lou, Y., Jones, M. P., and Sun, W. (2019), “Estimation of Causal Effects in Clinical Endpoint Bioequivalence Studies in the Presence of Intercurrent Events: Noncompliance and Missing Data,” Journal of Biopharmaceutical Statistics, 29, 151–173. DOI: 10.1080/10543406.2018.1489408.
   PubMed Web of Science ®Google Scholar
• Louizos, C., Shalit, U., Mooij, J., Sontag, D., Zemel, R., and Welling, M. (2017), “Causal Effect Inference With Deep Latent-Variable Models,” arXiv no. 1705.0882.
   Google Scholar
• Mallinckrodt, C. H. (2013), Preventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide, Cambridge: Cambridge University Press.
   Google Scholar
• Magnusson, B. P., Schmidli, H., Rouyrre, N., and Scharfstein, D. O. (2018), “Bayesian Inference for a Principal Stratum Estimand to Assess the Treatment Effect in a Subgroup Characterized by Post-Randomization Events,” arXiv no. 1809.03741.
   Google Scholar
• National Research Council (2010), The Prevention and Treatment of Missing Data in Clinical Trials, Washington, DC: National Academies Press.
   Google Scholar
• Permutt, T. (2016), “A Taxonomy of Estimands for Regulatory Clinical Trials With Discontinuations,” Statistics in Medicine, 35, 2865–2875. DOI: 10.1002/sim.6841.
   PubMed Web of Science ®Google Scholar
• Ratitch, B., and O’Kelly, M. (2018), “Effects in Adherent Subjects,” Statistics in Biopharmaceutical Research, 10, 233–235.
   Web of Science ®Google Scholar
• Ratitch, B., and O’Kelly, M. (2011), “Implementation of Pattern-Mixture Models Using Standard SAS/STAT Procedures,” PharmaSUG Paper-SP04, available at http://pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf.
   Google Scholar
• Robins, J. M. (1989), “The Analysis of Randomized and Non-Randomized AIDS Treatment Trials Using a New Approach to Causal Inference in Longitudinal Studies,” in Health Service Research Methodology: A Focus on AIDS, eds. L. Sechrest, H. E. Freeman, and A. G. Mulley, pp. 113–159.
   Google Scholar
• Robins, J. M., Hernán, M. A., and Brumback, B. (2000), “Marginal Structural Models Versus Structural Nested Models as Tools for Causal Inference,” in Statistical Models in Epidemiology, the Environment, and Clinical Trials, eds. M. Elizabeth Halloran and D. Berry, New York: Springer, pp. 95–133.
   Google Scholar
• Robins, J. M., Hernán, M. A., and Brumback, B. (2000), “Marginal Structural Models and Causal Inference in Epidemiology,” Epidemiology, 11, 550–560. DOI: 10.1097/00001648-200009000-00011.
   PubMed Web of Science ®Google Scholar
• Ruberg, S. J., and Akacha, M. (2017), “Considerations for Evaluating Treatment Effects From Randomized Clinical Trials,” Clinical Pharmacology & Therapeutics, 102, 917–923. DOI: 10.1002/cpt.869.
   PubMed Web of Science ®Google Scholar
• Rubin, D. B. (1976), “Inference and Missing Data,” Biometrika, 63, 581–592. DOI: 10.1093/biomet/63.3.581.
   Web of Science ®Google Scholar
• Sklar, A. (1980), “Randomization Analysis of Experimental Data: The Fisher Randomization Test Comment,” Journal of the American Statistical Association, 75, 591–593.
   Google Scholar
• Sklar, A. (1959), “Fonctions de répartition á n dimensions et leurs marges,” Publications de l’Institut Statistique de l’Université de Paris, 8, 229–231.
   Google Scholar
• Sutter, S. (2017), “Kevzara: Sanofi Caught in Middle of US FDA Debate on Data Analysis,” The Pink Sheet, available at https://pink.pharmaintelligence.informa.com/PS121332/Kevzara-Sanofi-Caught-In-Middle-Of-US-FDA-Debate-On-Data-Analysis.
   Google Scholar
• Tao, Y., and Fu, H. (2017), “Robust Estimation of the Weighted Average Treatment Effect for a Target Population,” arXiv no. 1804.05079.
   Google Scholar